Talix delivers NLP powered, integrated workflow applications to improve the speed and accuracy of risk adjustment coding. Our proven applications serve health plans (first pass, second pass, and claims validation) and healthcare providers and coders (retrospective, concurrent and prospective uses) at the point of care. Talix’s sophisticated reporting and analytics capabilities provide better visibility and increased predictability of risk adjustment operations and financial performance.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BIOTECHNOLOGY LEADER LUMINULTRA SUBMITS COVID-19 CLINICAL DIAGNOSTIC TESTING KIT FOR REGULATORY AUTHORIZATION IN U.S., CANADA

LuminUltra | September 14, 2020

news image

Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be custom...

Read More

Industrial Impact, Medical

EMULATE PUBLISHES LANDMARK STUDY VALIDATING ORGAN-ON-A-CHIP TECHNOLOGY FOR PREDICTIVE TOXICOLOGY IN PRECLINICAL DEVELOPMENT

Emulate, Inc. | December 07, 2022

news image

Emulate, Inc., the leading provider of next-generation in vitro models announced the publication of a landmark study, “Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology,” in Nature Communications Medicine demonstrating that the Emulate human Liver-Chip could improve patient safety and reduce small-molecule clinical trial failures due to liver toxicity by up to 87%. These findings conclude the single largest Organ-Chip study to date, in which...

Read More

Industrial Impact

QUANTUM GENOMICS SIGNS AN EXCLUSIVE LICENSE AND PRODUCTION AGREEMENT WITH GULF PHARMACEUTICALS INDUSTRIES JULPHAR

Quantum Genomics | December 06, 2021

news image

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...

Read More

Research

IMMAGENE AND SELVITA ANNOUNCE INTEGRATED DRUG DISCOVERY COOPERATION

Selvita | February 07, 2022

news image

Immagene a Dutch biotech company developing transformational next-generation precision immuno-oncology treatments, and Selvita, one of the largest preclinical contract research organizations in Europe, announce their cooperation on an integrated drug discovery project. Immagene and Selvita have been closely cooperating over the past year on a novel integrated drug discovery project to enhance the clinical benefit of immuno-oncology therapies. In this ongoing effort, Immagene is gu...

Read More
news image

BIOTECHNOLOGY LEADER LUMINULTRA SUBMITS COVID-19 CLINICAL DIAGNOSTIC TESTING KIT FOR REGULATORY AUTHORIZATION IN U.S., CANADA

LuminUltra | September 14, 2020

Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be custom...

Read More
news image

Industrial Impact, Medical

EMULATE PUBLISHES LANDMARK STUDY VALIDATING ORGAN-ON-A-CHIP TECHNOLOGY FOR PREDICTIVE TOXICOLOGY IN PRECLINICAL DEVELOPMENT

Emulate, Inc. | December 07, 2022

Emulate, Inc., the leading provider of next-generation in vitro models announced the publication of a landmark study, “Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology,” in Nature Communications Medicine demonstrating that the Emulate human Liver-Chip could improve patient safety and reduce small-molecule clinical trial failures due to liver toxicity by up to 87%. These findings conclude the single largest Organ-Chip study to date, in which...

Read More
news image

Industrial Impact

QUANTUM GENOMICS SIGNS AN EXCLUSIVE LICENSE AND PRODUCTION AGREEMENT WITH GULF PHARMACEUTICALS INDUSTRIES JULPHAR

Quantum Genomics | December 06, 2021

Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...

Read More
news image

Research

IMMAGENE AND SELVITA ANNOUNCE INTEGRATED DRUG DISCOVERY COOPERATION

Selvita | February 07, 2022

Immagene a Dutch biotech company developing transformational next-generation precision immuno-oncology treatments, and Selvita, one of the largest preclinical contract research organizations in Europe, announce their cooperation on an integrated drug discovery project. Immagene and Selvita have been closely cooperating over the past year on a novel integrated drug discovery project to enhance the clinical benefit of immuno-oncology therapies. In this ongoing effort, Immagene is gu...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us